More recently developed monotherapies to treat obesity such as the long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, liraglutide and semaglutide (4), produce more pronounced effects on weight loss relative to previous analogues. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.